drugset / Trial / NCT02392130

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

NCT02392130

Phase 1 Completed 40 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindOther

Summary

The purpose of this study is to assess the effect of LEO 130852A gel 1% in maintaining skin thickness in healthy skin treated with steroid.

Timeline

Start
2015-03
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 130852A Unknown 1 %
Comparator clobetasol propionate Small molecule 0.05 %